Author: Qahwa World |
Date: July 2, 2026
Coffee Linked to Lower Risk of Cirrhosis and Liver Cancer in Large Study
Key Findings:
- Study of over 354,000 UK Biobank participants followed for a median of 13 years.
- Five or more cups of coffee daily linked to 32% lower risk of cirrhosis, 47% lower risk of liver cancer, and 42% lower risk of liver-related death.
- The association followed a dose-response pattern: more coffee, lower risk.
- Similar results for caffeinated and decaffeinated coffee, suggesting non-caffeine compounds play a protective role.
- Adding sugar or sweeteners did not eliminate benefits but was linked to markers of liver inflammation and fibrosis.
- Proteomic analysis identified 74 proteins associated with coffee intake and reduced fibrosis risk.
A large-scale study of over 354,000 participants from the UK Biobank has found that higher coffee consumption is associated with significantly lower risks of cirrhosis, liver cancer, and liver-related death. The findings, published in Clinical Gastroenterology and Hepatology, also identified MRI and blood protein changes that may help explain the biological mechanisms behind the association.
The study followed participants for a median of 13 years. Researchers assessed self-reported coffee consumption, including coffee type and whether participants added sugar or artificial sweeteners. They then examined how these habits were associated with new cases of liver disease, MRI measures of liver health in a subgroup of 28,961 patients, and blood protein profiles in 44,633 patients.
The Numbers: Striking Reductions in Risk
Compared with non-coffee drinkers, those who consumed five or more cups daily were:
- 32% less likely to develop cirrhosis.
- 47% less likely to develop hepatocellular carcinoma.
- 42% less likely to die from liver disease.
The association followed a dose-response pattern, with lower risks observed starting at one to two cups per day. Similar findings were observed for both caffeinated and decaffeinated coffee, suggesting that compounds other than caffeine may play a protective role.
| Condition | Risk Reduction (5+ cups/day) |
|---|---|
| Cirrhosis | 32% |
| Hepatocellular Carcinoma | 47% |
| Liver-Related Death | 42% |
Sugar and Sweeteners: Mixed Effects
Researchers also examined whether adding sugar or artificial sweeteners changed the association between coffee and liver health. Overall, patients who added sweeteners had similar reductions in the risk of cirrhosis, hepatocellular carcinoma, and liver-related death compared to those who drank unsweetened coffee. However, they had 1.36 times the odds of elevated iron-corrected T1, an MRI marker of liver inflammation and fibrosis, compared with patients who did not add sweeteners.
MRI Findings: Benefits Visible Before Symptoms Appear
MRI results suggested that higher coffee intake was associated with better liver health before liver disease became clinically apparent. Patients who drank at least five cups daily had less liver fat, lower liver iron levels, and lower odds of liver fibroinflammation than non-coffee drinkers. The findings were similar for caffeinated and decaffeinated coffee, further supporting the role of non-caffeine compounds in liver protection.
Proteomic Analysis: 74 Proteins Point to Potential Mechanisms
Proteomic analyses identified 74 proteins associated with both coffee intake and cirrhosis risk, suggesting biological pathways related to liver function, inflammation, fibrosis, and immune regulation. These findings may help explain coffee’s observed associations with better liver health and provide new mechanistic clues.
Expert Insight: Interview with Lead Researcher Dr. Hyunseok Kim
Clinical Gastroenterology and Hepatology invited study author Dr. Hyunseok Kim of the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai Medical Center to comment on the implications of this work.
Q: Why does this study matter?
Dr. Kim: Coffee has long been associated with better liver health, but most previous studies focused only on clinical outcomes such as cirrhosis or liver cancer. Our study is unique because it integrates clinical outcomes with advanced MRI biomarkers and large-scale plasma proteomics in more than 350,000 UK Biobank participants. By combining these complementary approaches, we were able to show not only that coffee consumption is associated with lower risks of cirrhosis, hepatocellular carcinoma, and liver-related mortality, but also that it is linked to less liver fat, less fibroinflammation on MRI, and favorable biological pathways involved in fibrosis and inflammation. This provides stronger biological evidence supporting coffee as a simple lifestyle factor that may promote liver health.
Q: Was there a finding that surprised you?
Dr. Kim: Several findings stood out. First, we observed remarkably consistent associations across clinical outcomes, imaging biomarkers, and proteomic signatures, all pointing in the same direction. Second, both caffeinated and decaffeinated coffee showed similar associations, suggesting that compounds other than caffeine likely contribute to the liver benefits. Finally, we were intrigued that coffee drinkers had lower levels of proteins involved in fibrosis, macrophage activation, and extracellular matrix remodeling, while proteins reflecting healthier liver synthetic function were higher. These findings offer new mechanistic clues that go beyond the epidemiologic associations reported previously.
Q: How might the findings influence clinical practice?
Dr. Kim: This study should not be interpreted as evidence that coffee is a treatment for chronic liver disease. However, for most patients without contraindications, moderate coffee consumption appears to be a safe, inexpensive, and potentially beneficial lifestyle habit that can complement other evidence-based interventions such as weight loss, alcohol abstinence, and management of metabolic risk factors. I hope these findings will give clinicians greater confidence when discussing dietary habits with patients and encourage further research into the biological mechanisms underlying coffee’s protective effects.
Limitations and Recommendations: A Simple Prevention Strategy
The authors noted several limitations, including self-reported coffee intake, the possibility of unmeasured confounding and reverse causation, a healthier MRI subgroup, and the predominantly European ancestry of the study population, which may limit the generalizability of the findings. They also noted that the blood protein findings require experimental studies to confirm the underlying biological mechanisms.
Nevertheless, the authors concluded that “higher coffee intake was associated with lower risks of cirrhosis, HCC, and liver-related mortality, as well as favorable MRI-based and proteomic profiles.” They added that the combined clinical, imaging, and molecular findings support coffee as “a simple, scalable strategy for liver disease prevention.”
Frequently Asked Questions About Coffee and Liver Health
Q: How many cups of coffee are needed to reduce liver disease risk?
A: The study showed benefits starting at one to two cups daily, with more pronounced effects at five or more cups per day.
Q: Does decaffeinated coffee offer the same benefits?
A: Yes. Similar associations were observed for both caffeinated and decaffeinated coffee, suggesting non-caffeine compounds play a protective role.
Q: Does adding sugar negate coffee’s benefits?
A: Adding sugar or sweeteners did not eliminate the main benefits but was linked to markers of liver inflammation and fibrosis, so excessive additions should be avoided.
Q: Can coffee be considered a treatment for liver disease?
A: No. The study does not prove that coffee is a treatment. However, moderate consumption may be a beneficial complement to standard interventions.
Q: What biological mechanisms might explain coffee’s protective effects?
A: The study identified 74 proteins linked to reduced inflammation and fibrosis, suggesting multiple biological pathways may explain the benefits.
This study adds to the growing evidence on coffee’s potential health benefits, particularly for liver health. With risk reductions of up to 47%, coffee emerges as a simple, accessible tool for preventing chronic liver disease. However, further experimental studies are needed to confirm the biological mechanisms and determine optimal intake. In the meantime, coffee lovers can continue to enjoy their favorite beverage with greater awareness of its potential benefits.
Prepared and edited by: Qahwa World – Based on the study published in Clinical Gastroenterology and Hepatology on July 1, 2026.
Original source: Doug Brunk – Medical Report.
All rights reserved. Republication with attribution permitted.
Publication date: July 2, 2026
